Sitagliptin Phosphate is a medicine used to treat Type 2 diabetes. It helps lower blood sugar levels. It works by increasing certain hormones in your body that help control sugar. It's often taken once a day.
Every report comes from a Lived member, sent anonymously.
Have you tried Januvia (Sitagliptin Phosphate) for Type 2 Diabetes?
Sitagliptin, best known by the brand name Januvia, is a prescription medicine that lowers blood sugar in adults with type 2 diabetes. It is meant to work alongside eating habits and physical activity, not in place of them. It can be used on its own or combined with other diabetes medicines, such as metformin or insulin. It is not a treatment for type 1 diabetes, and it has not been shown to help children and teenagers with type 2 diabetes. Sitagliptin belongs to a group of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors). Its appeal is that it is a once-daily pill that seldom causes low blood sugar on its own and does not usually cause weight gain. The trade-off is that it lowers blood sugar less than many other options. The same ingredient is also available as generic sitagliptin tablets, as a liquid (Brynovin), and in combination tablets with metformin, such as Janumet and Janumet XR.
When you eat, the intestine releases hormones called incretins, mainly GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These hormones prompt the pancreas to release more insulin, and GLP-1 also reduces glucagon, a hormone that tells the liver to release stored sugar. An enzyme called DPP-4 normally breaks these hormones down quickly, which limits how long they act. Sitagliptin blocks DPP-4, so the body's own incretins stay active longer. The result is more insulin and less glucagon, which brings blood sugar down. Importantly, this boost happens mainly when blood sugar is normal or high, so sitagliptin by itself rarely pushes blood sugar too low.
Sitagliptin is taken by mouth once a day, with or without food. The usual adult dose is 100 mg; in studies, a higher dose did not lower blood sugar any further. Taking it at about the same time each day makes it easier to remember. If a dose is missed, take it when you remember unless the next dose is nearly due, and do not take two doses to make up for one. The right dose depends on kidney function, so a blood test is done before starting and repeated from time to time. The result is reported as an eGFR (estimated glomerular filtration rate), a measure of how well the kidneys filter blood; lower numbers mean the kidneys are filtering less. When eGFR is below 45, the dose is usually reduced to 50 mg a day, and below 30, or for people on dialysis, to 25 mg a day. Some reports of kidney injury with sitagliptin involved people taking doses too high for their kidney function, so a change in kidney results is a good reason to confirm the dose still fits. The liquid form is measured with an oral syringe or dosing cup, not a household spoon. Combination tablets that also contain metformin have their own dosing instructions.
Most people notice few side effects. In clinical trials, the problems reported more often than with a placebo (an inactive pill) were cold-like symptoms, such as a stuffy or runny nose and sore throat, and headache. Nausea, diarrhea and stomach discomfort can happen but were uncommon. Taken without insulin or a sulfonylurea, sitagliptin rarely causes low blood sugar. Rarely, sitagliptin can cause pancreatitis, an inflammation of the pancreas that can be serious. The typical sign is severe abdominal pain that does not go away, sometimes spreading to the back, with or without vomiting. If that happens, stop taking sitagliptin and contact the prescriber right away. Serious allergic reactions are also rare and usually start within the first three months, sometimes after the first dose. A new rash, hives, or blistering or peeling skin means stopping the medicine and contacting the care team promptly. Swelling of the face, lips, tongue or throat, or trouble breathing or swallowing, is an emergency: call 911. Medicines in this group have also been linked to severe joint pain, which can begin anywhere from a day to years after starting and usually eases once the medicine is stopped. A related rare problem is bullous pemphigoid, an immune skin condition that causes large, tense blisters. Tell the care team about either one so they can decide whether sitagliptin is the cause.
Sitagliptin should not be taken by anyone who has had a serious allergic reaction to it. People who have had pancreatitis are generally advised to avoid it and similar incretin-based medicines, since it has not been studied in them and the risk is unknown. Low blood sugar (hypoglycemia) becomes more likely when sitagliptin is added to insulin or to a sulfonylurea, an older type of diabetes pill, such as glipizide or glimepiride, that prompts the pancreas to release insulin. The prescriber may lower the dose of those medicines when sitagliptin starts, and anyone on these combinations should know how to recognize and treat a low. Sitagliptin is generally not combined with a GLP-1 medicine such as semaglutide (Ozempic, Wegovy) or with tirzepatide (Mounjaro, Zepbound). Those medicines act on the same hormone system, and adding sitagliptin brings no further drop in blood sugar. Two other DPP-4 inhibitors were linked to heart failure in large trials. A large trial of sitagliptin in people with diabetes and heart disease did not find more hospital stays for heart failure, but people who already have heart failure or reduced kidney function should weigh this with their prescriber. Increasing shortness of breath, rapid weight gain or swelling in the feet should be reported to the care team as soon as possible. There is too little information to know whether sitagliptin affects a developing baby, while poorly controlled diabetes in pregnancy clearly carries risks. Anyone pregnant, planning pregnancy or breastfeeding should review the diabetes plan with their care team.
Sitagliptin works quietly, so most people do not feel different day to day. Its effect shows up in blood sugar readings and in the A1C test, which reflects average blood sugar over about the past three months. In studies of adults whose A1C was around 8%, sitagliptin lowered A1C by about 0.6 percentage points more than a placebo over 18 to 24 weeks. That is a modest effect compared with insulin and GLP-1 medicines such as semaglutide, so sitagliptin is often one part of a plan rather than the whole plan, and the plan may change if A1C stays above the agreed goal. Sitagliptin is weight neutral. A large trial showed it did not raise the risk of heart attack, stroke or heart failure in people with heart disease, but it also did not lower that risk. For people with heart disease, heart failure or chronic kidney disease, medicines with proven protective benefits, such as GLP-1 medicines and SGLT2 inhibitors (a class of diabetes pills that also protect the heart and kidneys), are often preferred. Sitagliptin controls blood sugar but does not cure diabetes, so it is usually taken long term and continued even when someone feels well. Follow-up includes regular A1C checks and periodic kidney tests. Stopping or changing it is a decision to make with the prescriber, since blood sugar can rise again without a replacement.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Januvia (Sitagliptin Phosphate), what you've noticed, or ask the community a question.